{"entity":{"id":"nct06667141","kind":"trial","name":"Study of ACR-2316 in Specific Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of ACR-2316 run by Acrivon Therapeutics, now recruiting.","summary":"Study of ACR-2316 in Specific Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06667141 by Acrivon Therapeutics, with 100 participants planned, started 2024-10-08. Conditions recorded: Specific Advanced Solid Tumors. Interventions recorded: ACR-2316.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06667141","url":"https://clinicaltrials.gov/study/NCT06667141"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["acr-2316"],"companies":["acrivon-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06667141","phase":"1/2","setting":"ACR-2316-101: Phase 1/2 Study of ACR-2316 in Subjects With Advanced Solid Tumors","sponsor":"Acrivon Therapeutics","enrolled":100,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06667141/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"acr-2316","kind":"drug","name":"ACR-2316","route":"/drugs/acr-2316/"}],"company":[{"id":"acrivon-therapeutics","kind":"company","name":"Acrivon Therapeutics","route":"/companies/acrivon-therapeutics/"}]}}